From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.

ABSTRACT: Not until the turn of this century has immunotherapy become a fundamental component of cancer treatment. While monotherapy with immune modulators, such as immune checkpoint inhibitors, provides a subset of patients with durable clinical benefit and possible cure, combination therapy offers the potential for antitumor activity in a greater number of patients. The field of immunology has provided us with a plethora of potential molecules and pathways to target. This abundance makes it impractical to empirically test all possible combinations efficiently. We recommend that potential immunotherapy combinations be chosen based on sound rationale and available data to address the mechanisms of primary and acquired immune resistance. Novel trial designs may increase the proportion of patients rec

SUBMITTER: Day D 

PROVIDER: S-EPMC5736967 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature